Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021

Shockwave Medical, Inc. (Nasdaq: SWAV) will report its third quarter financial results on November 8, 2021, after market close.

Rhea-AI Summary

Shockwave Medical, Inc. (Nasdaq: SWAV) will report its third quarter financial results on November 8, 2021, after market close. A conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET, which investors can access by calling (866) 795-9106 domestically or (470) 495-9173 internationally, using conference ID: 9166273. Shockwave Medical focuses on innovative treatment for calcified cardiovascular disease through its Intravascular Lithotripsy (IVL) technology, aiming to improve patient outcomes.

Argus Publication session

+0.88% session move Open Argus

Details

News Market Reaction – SWAV

In the trading session that priced this news, SWAV gained 0.88%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CLARA, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8, 2021. Company management will host a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.  

Investors interested in listening to the conference call may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 9166273. A live and archived webcast of the event will be available at https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Shockwave Medical report its third quarter earnings for 2021?

Shockwave Medical will report its third quarter earnings on November 8, 2021, after market close.

What time is the conference call for Shockwave Medical's Q3 2021 results?

The conference call for Shockwave Medical's Q3 2021 results is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.

How can I listen to Shockwave Medical's earnings call?

Investors can listen to Shockwave Medical's earnings call by calling (866) 795-9106 for domestic calls or (470) 495-9173 for international calls, using conference ID: 9166273.

What technology does Shockwave Medical focus on for treating cardiovascular disease?

Shockwave Medical specializes in Intravascular Lithotripsy (IVL) technology for treating calcified cardiovascular disease.